Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
CNBC sat in on an "empathy training" at Amazon PillPack's Somerville offices, which is part of new hire orientation.Technologyread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
The "Fast Money" traders said on Tuesday that mergers and acquisitions may keep pushing the biotechnology sector to new highs.
The iShares Nasdaq Biotechnology ETF (IBB) hit a high of $299 a share on Tuesday, its highest level since mid-January. The traders made their comments after Biogen shares jumped 9 percent Tuesday on a Wall Street Journal report of buyout interest from drug companies, including Merck and Allergan. A source later told CNBC that Allergan is unlikely to pursue the deal.
Trader Tim Seymour said that the Biogen deal "makes sense whether it happens or not."
He said, however, that M&A activity has been a part of the gains in the sector "for a long time." He explained that the industry saw less activity as it faced increased scrutiny from politicians and regulators.
"You've gotten to a place where moving the needle for some of these big biotech companies and big pharma is very, very difficult. There's no longer one big drug and therefore the pipelines need a lot more," Seymour said.
Trader Brian Kelly said that Tuesday's price action is "a big move for the size of the company." He stuck to his investment strategy of selling the biotech stocks on any strength because of the political risks heading into the general election. Kelly said, however, he wouldn't necessarily short the stocks.
Trader Guy Adami said that while the takeover interest is specific to Biogen, other companies in the sector look interesting. He said that Gilead Sciences has an "unbelievable balance sheet" and that the company could "make a move."
Tim Seymour is long APC, AVP, BAC, BBRY, CLF, DO, DVYE, EDC, EWZ, F, FB, FCX, FXI, GM, GOOGL, GRMN, GE, INTC, LQD, M, MCD, MPEL, NKE, RACE, RAI, RH, RL, SINA, T, TWTR, UA, VALE, VZ, XOM and short: SPY, XRT. His firm is long ABX, BABA, BIDU, CLF, EWZ, F, HD, KO, MCD, MPEL, NKE, PEP, PF, SAVE, SBUX, SINA, VALE, VIAB, WMT, WEN, YHOO, short HYG, IWM
Karen Finerman is long AAL, BAC, C, DAL, DRII, DRII calls, FB, FL, GOOG, GOOGL, JPM, LYV, KORS, KORS, KORS puts, M, MA, SEDG, SPY puts, UAL, URI, WIFI long call spreads. Her firm is long ANTM, AAPL, BAC, C, C calls, DRII, DRII calls, FB, GOOG, GOOGL, JPM, JPM calls, KORS, LYV, M, MOH, PLCE, SPY puts, URI, WIFI. Her firm is short IWM, MDY. Finerman is on the board of GrafTech International.
Brian Kelly is long Bitcoin, DXJ, GLD, SLV, US Dollar UUP. He is short the Swiss franc, euro and Japanese yen.
Guy Adami is long CELG, EXAS, GDX, INTC. Adami's wife, Linda Snow, works at Merck.